Thrombolytic treatment for thrombosis of a mitral valve prosthesis during pregnancy.
Nanas
J N
JN
University of Athens School of Medicine, Department of Clinical Therapeutics, Alexandra Hospital, Vas. Sophias Avenue & 2 K. Lourou Street, 11528, Athens, Greece.
Kontoyannis
S A
SA
Mitsibounas
D N
DN
Stamatelopoulos
S F
SF
D000328:Adult; D000925:Anticoagulants / Q000627:therapeutic use; D015150:Echocardiography, Doppler; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006350:Heart Valve Prosthesis / Q000009:adverse effects*; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D008943:Mitral Valve; D008946:Mitral Valve Stenosis / Q000601:surgery*; D011247:Pregnancy; D011249:Pregnancy Complications, Cardiovascular / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000209:etiology*; D011256:Pregnancy Outcome; D011475:Prosthesis Failure; D011654:Pulmonary Edema / Q000209:etiology; D012214:Rheumatic Heart Disease / Q000601:surgery*; D012770:Shock, Cardiogenic / Q000209:etiology; D013927:Thrombosis / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000209:etiology*; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use*; D016896:Treatment Outcome; D014859:Warfarin / Q000627:therapeutic use
D000925:Anticoagulants; D005343:Fibrinolytic Agents; D014859:Warfarin; D006493:Heparin; D010959:Tissue Plasminogen Activator